內科WEN, MING-SHIENMING-SHIENWENLEE, MING-TA MICHAELMING-TA MICHAELLEECHEN, JIN-JERJIN-JERCHENCHUANG, HUI-PINGHUI-PINGCHUANGLU, LIANG-SUEILIANG-SUEILUCHEN, CHIEN-HSIUNCHIEN-HSIUNCHENLEE, TSONG-HAITSONG-HAILEEKUO, CHI-TAICHI-TAIKUOKUAN, PEI-LIANGPEI-LIANGKUANCHEN, YING-FUYING-FUCHENWU, JER-YUARNJER-YUARNWUCHEN, YUAN-TSONGYUAN-TSONGCHEN2009-12-182018-07-112009-12-182018-07-112008http://ntur.lib.ntu.edu.tw//handle/246246/174612Polymorphisms in CYP 2C9 and VKOR C1 have been shown to be associated with warfarin dose requirements and could be used to predict warfarin dose . We conducted a prospective study in which warfarin dose was prescribed based on CYP 2C9 and VKOR C1 polymorphisms in 108 Han-Chinese patients without prior warfarin treatments. Using the genotype-based dosing, 83% of patients reached stable, therapeutic international normalized ratio (INR ) within 2 weeks of treatment initiation and none of the patients developed clinical bleeding or thromboembolic event. Ten percent (11) of patients with INR >4 and no clinical bleeding were detected during this study. At 12 weeks, 69% of the patients’maintenance doses matched the prediction. Dosing algorithms incorporating genetic factors, age, and body surface area were developed, which could explain up to 62% of the total variation (R2 of 0.62). This study demonstrated that pharmacogenetics- based dosing could improve time to stable, therapeutic INR , reduce adverse events, and achieve high sensitivity.en-USjournal article10.1038/sj.clpt.6100453